多模态脑成像后血管内治疗的肾脏安全性
DEFUSE 3 随机试验比较了对比剂多模态成像筛选后血管内治疗(EVT)与药物治疗的肾功能变化。182例患者中,24小时肌酐较基线平均下降,EVT组与药物组无差异,对比剂相关肾损伤比例也无差异,提示EVT前灌注成像未导致肾功能下降。
要点
- EVT前对比剂灌注成像未伴随肾功能下降证据。
- EVT组与药物组24小时肌酐相对变化无差异(6.3% vs 9.2%,P=0.294)。
- EVT组对比剂相关肾损伤4.4% vs 药物组2.2%,P=0.682。
核心结论
- EVT前灌注成像未伴随肾功能下降证据。
研究设计与样本
- DEFUSE 3随机试验人群(n=182,年龄69±13岁,51%女性),比较EVT与药物管理。
主要发现
- 平均肌酐从基线0.98±0.33 mg/dL降至24小时0.88±0.28 mg/dL(P<0.001)。
- EVT组相对基线降低6.3% vs 药物组9.2%,P=0.294;绝对降低-0.08±0.18 vs -0.12±0.18,P=0.135。
- EVT组中CT选择(-0.08±0.18)与MRI选择(-0.07±0.19)的24小时肌酐变化无差异,P=0.808;相对降低6.8% vs 4.8%,P=0.696。
- EVT组对比剂相关肾损伤4/91(4.4%)vs 药物组2/90(2.2%),P=0.682。
- EVT组中MRI选择1/22(4.6%)vs CT选择3/69(4.4%)的对比剂相关肾损伤分布均匀,P=1.0。
关键数值与推荐
- 主要结局为EVT组与药物组基线至24小时肌酐相对变化。
- 次要结局为EVT组中CT与MRI选择的比较。
- 安全结局为对比剂相关肾损伤比例比较。
临床怎么用
- 支持在延长时间窗内使用对比剂多模态成像筛选EVT患者。
- EVT前灌注成像未显示肾功能下降证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Contrast-enhanced noninvasive angiography and perfusion imaging are recommended to identify eligible patients for endovascular therapy (EVT) in extended time windows (>6 hours or wake-up). If eligible, additional intraarterial contrast exposure will occur during EVT. We aimed to study the renal safety in the DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke) population, selected with contrast-enhanced multimodal Imaging and randomized to EVT versus medical management. METHODS: In the randomized DEFUSE 3 trial population, we compared changes in serum creatinine between baseline (before randomization) and 24 hours later. The primary outcome was the relative change in creatinine level between baseline and 24 hours in the EVT versus medical arm. The secondary outcome was a comparison between computed tomography (CT) versus magnetic resonance imaging selection in the EVT arm. The safety outcome was a comparison of the proportion of patients with criteria for contrast-associated kidney injury in the EVT versus medical arm and a comparison between CT versus magnetic resonance imaging selection in the EVT arm. RESULTS: In the DEFUSE 3 population (n=182, age 69±13, 51% female), mean creatinine decreased from a baseline of 0.98±0.33 mg/dL to 0.88±0.28 mg/dL at 24 hours (P<0.001). There was no difference in change between treatment groups: relative to baseline, there was a 6.3% reduction in the EVT group versus 9.2% in the medical group, P=0.294. Absolute decrease -0.08±0.18 in EVT versus -0.12±0.18 in medical, P=0.135; Among patients treated with EVT, there was no difference in 24-hour creatinine level changes between patients who were selected with CT angiography/CT perfusion (-0.08±0.18) versus magnetic resonance imaging (-0.07±0.19), P=0.808 or 6.8% reduction versus 4.8%, P=0.696. In the EVT arm, contrast-associated kidney injury was encountered in 4 out of 91 (4.4%) versus 2/90 (2.2%) in the medical arm P=0.682. In the EVT arm, contrast-associated kidney injury was evenly distributed between magnetic resonance imaging (1/22, 4.6%) versus CT 3 out of 69 (4.4%), P=1.0. CONCLUSIONS: Perfusion imaging before EVT was not associated with evidence of decline in renal function. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02586415.
引用
- Cereda CW, Mlynash M, Cippà PE, et al. Renal Safety of Multimodal Brain Imaging Followed by Endovascular Therapy. Stroke. 2020. PMID: 33250038. doi:10.1161/STROKEAHA.120.030816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。